Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

The Consumer Healthcare Products Association requests 30 minutes to address the Nonprescription Drugs Advisory Committee during its meeting on Sept. 25. In its letter to FDA, CHPA attached rough guidelines as discussed at a February 2005 FDA roundtable regarding consumer behavior. CHPA said it has used the information from the roundtable and May 2005 Regulatory and Scientific Conference in "formulating our recommendations for refining the evaluation of studies to support marketing approval of OTC products." Former CHPA VP-Regulatory & Scientific Affairs Douglas Bierer will represent CHPA at the meeting. FDA announced the agenda of its NDAC meeting in Aug. 28 briefing documents (1"The Tan Sheet" Sept. 4, 2006, p. 3)...

You may also be interested in...

Advisory Panel Meeting Menu Includes Self-Selection Risk/Benefit Evaluation

FDA's Nonprescription Drugs Advisory Committee will tackle issues such as weighing the risks of self-selection failures against the benefit of successes when the panel convenes Sept. 25 to discuss OTC drug consumer behavior trials

LSI 2023: Intuitive Alums On Dawning Of Robotic Surgery To Digital OR Future

Robotic surgery pioneer and co-founder of Intuitive Surgical Frederic Moll joined Daniel Hawkins, Intuitive’s first non-technical hire, for a discussion on the evolution of surgical robotics and outlook for the future.

EU Sets New Date For Publication Of Delayed Pharma Revision Proposals

Lengthy legislative procedures are expected after the commission publishes its “pharma package” and the “patent package,” which are now due towards the end of April.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts